

Version with Markings to Show Changes Made:

In the Claims:

Please amend claims 29, 31, 46, 85, 99, and 101 to read as follows:

29. (Amended) A composition having a pH of [at least]about pH 5.5 or greater, wherein said composition comprises:

(a) biologically active insulin-like growth factor-1 (IGF-I) or biologically active analogue thereof having an amino acid sequence that shares at least 70% sequence identity with the amino acid sequence for human IGF-I, wherein said IGF-I or analogue thereof is present at a concentration of [at least]about 12 mg/ml or greater when said composition is at a temperature of about 4°C; and

(b) a solubilizing compound comprising a guanidinium group, wherein said solubilizing compound is present in said composition in an amount sufficient to make said IGF-I or analogue thereof soluble at a concentration of [at least]about 12 mg/ml or greater when said composition is at a temperature of about 4°C.

31. (Twice amended) The composition of claim 29, wherein said solubilizing compound is selected from the group consisting of arginine, N-acetyl-arginine, a dipeptide containing arginine, and a tripeptide containing arginine, wherein said dipeptide or said tripeptide increases solubility of said IGF-I or analogue thereof at a pH of [at least]about pH 5.5 or greater.

46. (Twice amended) A composition comprising:

(a) biologically active insulin-like growth factor-1 (IGF-I) or biologically active analogue thereof having an amino acid sequence that shares at least 70% sequence identity with the amino acid sequence for human IGF-I, wherein said IGF-I or analogue thereof is present at a concentration of [at least]about 12 mg/ml or greater when said composition is at a temperature of about 4°C;

(b) a solubilizing compound selected from the group consisting of arginine, N-acetyl-arginine, a dipeptide containing arginine, a tripeptide containing

arginine, and guanidine hydrochloride, wherein said dipeptide or said tripeptide increases solubility of said IGF-I or analogue thereof at a pH of [at least]about pH 5.5 or greater; and

(d) a buffer such that the composition has a pH of about pH 5.5 to about pH 9.0.

85. (Amended) A composition having a pH of [at least]about pH 5.5 or greater, wherein said composition comprises:

(a) biologically active human insulin-like growth factor-1 (IGF-I), wherein said IGF-I is present at a concentration of [at least]about 12 mg/ml or greater when said composition is at a temperature of about 4°C; and

(b) a solubilizing compound comprising a guanidinium group, wherein said solubilizing compound is present in said composition in an amount sufficient to make said IGF-I soluble at a concentration of [at least]about 12 mg/ml or greater when said composition is at a temperature of about 4°C.

99. (Amended) A composition comprising:

(a) biologically active human insulin-like growth factor-1 (IGF-I), wherein said IGF-I is present at a concentration of [at least]about 12 mg/ml or greater when said composition is at a temperature of about 4°C;

(b) a solubilizing compound selected from the group consisting of arginine and guanidine hydrochloride; and

(c) a buffer such that the composition has a pH of about pH 5.5 to about pH 9.0.

101. (Amended) A composition having a pH of [at least]about pH 5.5 or greater, wherein said composition comprises:

(a) biologically active human insulin-like growth factor-1 (IGF-I), wherein said IGF-I is present at a concentration of [at least]about 12 mg/ml or greater when said composition is at a temperature of about 4°C; and

(b) arginine in an amount sufficient to make said IGF-I soluble at a concentration of [at least]about 12 mg/ml or greater when said composition is at a temperature of about 4°C.